SVCM
INZY

Saturn V Capital Management’s Inozyme Pharma INZY Stock Holding History

Saturn V Capital Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-499,254
Closed -$454K – 26
2025
Q1 		$454K Sell
499,254
-875,328
-64% -$1.21M 0.23% 21
2024
Q4 		$3.81M Buy
1,374,582
+5,772
+0.4% +$22K 1.49% 17
2024
Q3 		$7.16M Buy
1,368,810
+228,500
+20% +$1.19M 2.56% 15
2024
Q2 		$5.09M Buy
+1,140,310
New +$5.53M 1.92% 20

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Saturn V Capital Management's INZY Position: Q2 2025 in Review

Saturn V Capital Management sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 499,254 shares — an estimated $454K sold.

Saturn V Capital Management first reported a position in INZY in Q2 2024 and held it in 4 quarters. The position peaked at $7.16M in Q3 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Saturn V Capital Management reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 499,254 Inozyme Pharma shares in Q2 2025, an estimated $454K.
  • Saturn V Capital Management first reported a position in Inozyme Pharma in Q2 2024 and held it in 4 quarters.
  • Saturn V Capital Management's Inozyme Pharma position peaked at $7.16M in Q3 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Saturn V Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.